Results 141 to 150 of about 9,288 (216)

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis

European Respiratory Journal, 2023
Background Recent studies demonstrated that the triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves lung function and reduces pulmonary exacerbations in cystic ...
L. Schaupp, A. Addante, M. Völler, K. Fentker, A. Kuppe, M. Bardua, J. Duerr, L. Piehler, J. Röhmel, Stephanie Thee, Marieluise Kirchner, M. Ziehm, D. Lauster, R. Haag, M. Gradzielski, M. Stahl, Philipp Mertins, S. Boutin, S. Graeber, M. Mall   +19 more
semanticscholar   +1 more source

Ivacaftor

Drugs of the Future, 2012
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
null Raju, S.V., null Rowe, S.M.
  +4 more sources

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Canadian Journal of Health Technologies, 2022
What Is the CADTH Reimbursement Recommendation for Trikafta? CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years and older who have at least one F508del mutation in the CFTR gene, if certain conditions are met.
openaire   +1 more source

Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis

Thorax
Background Despite significant clinical improvements, there is evidence of persisting airway inflammation in people with cystic fibrosis (CF) established on elexacaftor/tezacaftor/ivacaftor (ETI) therapy.
R. Maher, U. Cytlak-Chaudhuri, S. Aleem, Peter J Barry, D. Brice, E. Caamaño Gutiérrez, K. Driver, E. Emmott, A. Rothwell, E. Smith, M. Travis, Dave Lee, Paul S. McNamara, I. Waller, J. Smith, A. Jones, R. Lord   +16 more
semanticscholar   +1 more source

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Yearbook of Pulmonary Disease, 2016
METHODS We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of ...
C. Wainwright, J. S. Elborn, B. Ramsey, G. Marigowda, X. Huang, M. Cipolli, C. Colombo, J. Davies, K. Boeck, P. Flume, M. Konstan, S. McColley, K. McCoy, E. McKone, A. Munck, F. Ratjen, S. M. Rowe, D. Waltz, M. P. Boyle   +18 more
semanticscholar   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase‐1 in Children With Cystic Fibrosis

Pediatric Pulmonology
Prior studies have documented improvement in pancreatic status after ivacaftor and lumacaftor/ivacaftor in a small number of patients with cystic fibrosis (CF).
S. Sankararaman, L. Prunty, Catherine Pamer, A. Thavamani, E. Roesch, T. Schindler   +5 more
semanticscholar   +1 more source